Appointment effective April 13, 2026123
Jeff Knight brings over 30 years of biopharma and oncology experience, including roles at Crinetics, Genentech, Amgen, Poseida, and Halozyme126
Aims to strengthen development for evorpacept and ALX2004 catalysts expected in next 12-18 months12
ALX Oncology (NASDAQ:
ALXO) is a clinical-stage biotech focused on cancer therapies12
Sources:
1. https://www.stocktitan.net/news/ALXO/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-zyhzndc9wsww.html
2. https://www.investing.com/news/company-news/alx-oncology-names-jeff-knight-as-chief-development-officer-93CH-4610441
3. https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-appoints-jeff-knight-chief-development-and
6. https://it.marketscreener.com/notizie/alx-oncology-holdings-inc-nomina-jeff-knight-chief-development-and-operating-officer-con-decorrenza-ce7e50dedc81fe26